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Background. Oseltamivir resistance in A(H1N1)pdm09 inﬂuenza is rare, particularly in untreated community
cases. Sustained community transmission has not previously been reported.
Methods. Inﬂuenza specimens from the Asia–Paciﬁc region were collected through sentinel surveillance, hos-
pital, and general practitioner networks. Clinical and epidemiological information was collected on patients infect-
ed with oseltamivir-resistant viruses.
Results. Twenty-nine (15%) of 191 A(H1N1)pdm09 viruses collected between May and September 2011 from
Hunter New England (HNE), Australia, contained the H275Y neuraminidase substitution responsible for oselta-
mivir resistance. Only 1 patient had received oseltamivir before specimen collection. The resistant strains were
genetically very closely related, suggesting the spread of a single variant. Ninety percent of cases lived within 50
kilometers. Three genetically similar oseltamivir-resistant variants were detected outside of HNE, including 1
strain from Perth, approximately 4000 kilometers away. Computational analysis predicted that neuraminidase sub-
stitutions V241I, N369K, and N386S in these viruses may offset the destabilizing effect of the H275Y substitution.
Conclusions. This cluster represents the ﬁrst widespread community transmission of H275Y oseltamivir-
resistant A(H1N1)pdm09 inﬂuenza. These cases and data on potential permissive mutations suggest that currently
circulating A(H1N1)pdm09 viruses retain viral ﬁtness in the presence of the H275Y mutation and that widespread
emergence of oseltamivir-resistant strains may now be more likely.
Oseltamivir (Tamiﬂu®) is the most commonly used
drug for the treatment or prophylaxis of inﬂuenza,
and has been widely used in Japan, North America,
and Europe. Oseltamivir has also been stockpiled by
many countries as part of pandemic preparedness and
was widely used during the 2009 inﬂuenza A(H1N1)
pandemic, when it was shown to improve clinical out-
comes in infants, adults, and pregnant women [1–6].
Since the emergence of the pandemic H1N1 2009
virus (A[H1N1]pdm09), oseltamivir resistance has
been detected at a frequency of approximately 1%,
with the majority of resistant viruses being isolated
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treatment [7–9]. Virtually all of these resistant viruses have
contained the histidine (H) to tyrosine (Y) substitution at po-
sition 275 of the neuraminidase (NA; N1 numbering—the
same substitution is referred to as H274Y based on N2 num-
bering), which confers highly reduced oseltamivir sensitivity
in vitro [10]. This substitution was also present in the oselta-
mivir-resistant variant of the prepandemic seasonal A(H1N1)
subtype that emerged in Europe and then spread globally in
less than a year in 2008 [11,12]. This demonstrated the capac-
ity of an A(H1N1) virus to overcome the inherently detrimen-
tal ﬁtness effect of the H275Y substitution [13,14] and
transmit readily between individuals in the absence of drug
selection pressure. Clinical data have shown that the effective-
ness of oseltamivir was signiﬁcantly reduced during the treat-
ment of the previously circulating seasonal A(H1N1) H275Y
variants [15–18].
Transmission of oseltamivir-resistant H275Y A(H1N1)
pdm09 strains to date has been limited or unsustained. Most
commonly, transmission has occurred in closed, near-contact
settings, such as hospital wards [19–21], or after prolonged
close contact in community settings such as a long train
journey or at a school camp [22,23]. Oseltamivir-resistant
H275Y variants were detected at a low frequency (<1%) among
community cases during the 2010–2011 northern hemisphere
inﬂuenza season [24,25]and, based on our testing, this contin-
ues to be the case for most countries in the southern
hemisphere during the current 2011 inﬂuenza season. In con-
trast, between June and August 2011, in the Hunter New
England region around Newcastle, Australia, we detected a sig-
niﬁcantly increased frequency of H275Y oseltamivir-resistant
A(H1N1)pdm09 viruses in community patients, of whom only
1 patient had been treated with oseltamivir [26]. Following our
initial brief report [26], here we describe the virological and
epidemiological aspects of the cluster of H275Y oseltamivir-re-
sistant A(H1N1)pdm09 inﬂuenza and discuss potentially per-
missive NA substitutions that may have enabled the A(H1N1)
pdm09 virus to retain viral ﬁtness in the presence of the
H275Y mutation.
MATERIALS AND METHODS
Sample Collection
Newcastle (population 273805) is a regional coastal city in
the state of New South Wales (NSW), and the sixth largest
city in Australia, providing tertiary referral specialist services
for northern NSW. It is located approximately 120 kilometers
north of the NSW capital, Sydney (Figure 1). The Hunter
New England (HNE) health district, of which Newcastle is the
major city, stretches from Lake Macquarie in the south to the
Queensland border. The HNE health district is served
by Hunter Area Pathology Services (HAPS), which receive
specimens for inﬂuenza testing from emergency departments,
intensive care units, and general practitioners. Respiratory
Figure 1. Map of the Hunter New England (HNE) health district and Australia. HNE health district is colored in red.
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positive for inﬂuenza A or B by nucleic acid testing at
HAPS in 2011 were referred weekly to the World Health
Organization (WHO) Collaborating Centre for Reference and
Research on Inﬂuenza (WHO CCRRI) for further virological
analysis. A(H1N1)pdm09 viruses from the HNE health district
were compared with viruses obtained from WHO National In-
ﬂuenza Centres that form part of the WHO Global Inﬂuenza
Surveillance and Response System (GISRS), and other labora-
tories both within and outside of Australia.
To enable the review of oseltamivir-resistant viruses in
the HNE health district, the NSW Chief Health Ofﬁcer
granted an ethics waiver and authorized the investigation
under the NSW Public Health Act 2010 as an urgent public
health investigation. For all patients with oseltamivir-resistant
viruses, hospital records were reviewed and treating medical
practices contacted to obtain details of clinical symptoms and
outcomes, antiviral and concomitant treatment administered
during the current and previous treatment episodes, and
medical history. Patients infected with oseltamivir-resistant
inﬂuenza viruses were interviewed using a structured question-
naire to gather data on patient demographics, medical history
of immune-compromising conditions, inﬂuenza vaccination
status in 2011, and antiviral treatment history.
Virological Analysis
Viruses were isolated from original clinical samples and repas-
saged in Madin–Darby canine kidney cells (ATCC CCL-34).
Antigenic characterization was performed using a hemaggluti-
nation-inhibition assay [27]. All virus isolates were analyzed
for oseltamivir, zanamivir, and peramivir sensitivity using a
ﬂuorescence-based NA inhibition assay [28], followed by hem-
agglutinin (HA) and NA sequence analysis of those strains
with elevated inhibitory concentration (IC50) values (the con-
centration of drug required to inhibit the NA activity by 50%).
Where virus isolates could not be obtained, original specimens
were analyzed for the presence or absence of the H275Y NA
substitution using a pyrosequencing assay [29]. The HA and
NA genes were fully sequenced using standard techniques on
an ABI 3500XL sequencer. Sequences from oseltamivir-resis-
tant strains were uploaded to a publically available inﬂuenza
sequence database (GISAID; www.gisaid.org), and given acces-
sion numbers EPI334765-334790 and 335634-335637.
Maximum likelihood phylogenetic trees were constructed with
PhyML (http://www.atgc-montpellier.fr/phyml) using HKY85
as the nucleotides substitution model with bootstrapping
(Geneious Pro 5.1.4 software).
Computational Structural Analysis
Computational structural analysis of combinations of candi-
date permissive mutations in the NA was conducted
using FoldX [31], an empirical all-atom force ﬁeld that
allows the calculation of protein stability changes upon muta-
tion by approximating the free energy of unfolding through
weighted terms. To validate the calculations, more than 1000
mutations representative of most structural environments were
analyzed and achieved a global correlation of 0.8 with experi-
mentally measured thermodynamic data. In this work, the A
(H1N1)pdm09 NA crystal structure (PDB:3nss) was mini-
mized with the RepairPDB function, then mutations were in-
troduced separately or as cumulative combinations using
FoldX in YASARA [32], where the stochastic side chain mini-
mization procedure is repeated 5 times for each mutant and
the averages are taken as ﬁnal predicted free-energy change.
Results
Frequency of Oseltamivir Resistance
From the HNE health district, 2673 respiratory tract speci-
mens were collected for inﬂuenza testing by nucleic acid
testing (NAT) at HAPS in the period 20 May 2011 to 28
October 2011 (23 weeks) from a population of 874 644 (0.3%).
Of the 749 inﬂuenza NAT-positive specimens, 439 (59%) were
A(H1N1)pdm09 viruses (Figure 2) and 191 had sufﬁcient
volume to enable antiviral susceptibility analysis by the WHO
CCRRI. Twenty-nine (15%) of these 191 A(H1N1)pdm09
viruses were found to contain the H275Y NA substitution by
either pyrosequencing of original specimens (n =18) or con-
ventional NA sequencing of isolates following an NA inhibi-
tion assay (n= 11). H275Y A(H1N1)pdm09 viruses were
obtained from patients between 31 May and 19 August 2011
(Figure 3). The frequency of resistance over time was 4/51
(8%) in June, 20/85 (24%) in July, 4/45 (8%) in August, and
0/4 (0%) in September by which time inﬂuenza activity had
become very low in the region (Figure 2). Twenty-six of the 29
patients infected with oseltamivir-resistant viruses lived in 5
adjacent local municipalities (Cessnock, Lake Macquarie,
Maitland, Newcastle, Port Stephens) within 50 kilometers of
Newcastle. The other 3 patients lived in rural towns 90, 150,
and 490 kilometers away from Newcastle.
In comparison, only 5 oseltamivir-resistant H275Y viruses
were detected out of 737 A(H1N1)pdm09 viruses tested (fre-
quency, 0.7%) from the rest of Australia during 2011
(Figure 3). Two of these strains from January and March 2011
were from other Australian states (Queensland and Western
Australia) and were isolated from hospitalized immunocom-
promised patients undergoing oseltamivir treatment. However,
2 oseltamivir-resistant H275Y viruses from elsewhere in NSW
and 1 from Western Australia were collected during or after
the period of oseltamivir-resistant virus detection in the HNE
health district. One of the NSW oseltamivir-resistant viruses
was detected in July 2011 from a child in Sydney, NSW, 120
kilometers south of Newcastle, while the other was detected in
August 2011 from an infant in Orange, NSW, a town
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Australian oseltamivir-resistant virus was detected in Septem-
ber 2011, 3 weeks after the last detected case in the HNE
health district, and in a location near Perth, approximately
4000 kilometers west of Newcastle. All 3 of these resistant
viruses were taken from otherwise healthy children who had
not been treated with oseltamivir. Neither they nor their
family members had traveled recently to Newcastle, and in the
Western Australian case, there had been no recent contact
with anyone from NSW.
Figure 2. Number of laboratory-conﬁrmed inﬂuenza positive specimens detected in the Hunter New England health district during 2011.
Figure 3. Frequency of detection of oseltamivir-resistant H275Y variants in Australia in 2011. A red dot represents the sample date of an individual
oseltamivir-resistant A(H1N1)pdm09 H275Y case, and a blue dot indicates the sample date of an individual oseltamivir-sensitive A(H1N1)pdm09 case
detected in the states and territories of Australia in 2011.
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Cases
Seventeen (59%) of the 29 patients infected with oseltamivir-
resistant viruses were female and 3 (10%) were pregnant. Three
(10%) identiﬁed themselves as Aboriginal. The age range was 4
months to 62 years (median, 31 years) compared with a
median age of 29 years for persons infected with oseltamivir-
sensitive inﬂuenza A(H1N1)pdm09. No cases resided in insti-
tutional care or aged care facilities. Cough was reported by 25
(86%) cases and fever by 22 (76%) cases. One patient was
asymptomatic, but was swabbed and tested for inﬂuenza due to
contact with a laboratory-proven A(H1N1)pdm09 case. Six
(21%) cases reported a history of asthma; none had a history of
chronic obstructive pulmonary disease; 6 (21%) were current
smokers with an average pack-year history of 20 (range, 1–62)
and none were immunosuppressed. Three (10%) cases had re-
ceived trivalent-inactivated inﬂuenza vaccine in 2011. Impor-
tantly, only 1 patient infected with an oseltamivir-resistant
virus had received oseltamivir prior to their specimen being
collected (in this case, received 4 days prior to specimen being
taken). Eleven (38%) were prescribed oseltamivir after speci-
men collection. Seven (24%) patients required hospital admis-
sion with a mean length of stay of 2.3 days (range, 1–7 days).
There were no intensive care admissions and no fatal out-
comes. The median number of days absent from usual duties
was 5. Of the 29 patients infected with an oseltamivir-resistant
virus, 5 pairs of cases were epidemiologically linked. Four
households had 2 affected cases each, while a ﬁfth pair of cases
shared a short car journey. No other links could be identiﬁed
during interviews with cases. Detailed outcomes were not col-
lected for persons infected with oseltamivir-sensitive inﬂuenza.
Virological Analysis of Oseltamivir-Resistant Viruses
For the viruses that were isolated in cell culture, the oseltami-
vir-resistant H275Y strains (n = 11) had a mean (±1 SD) osel-
tamivir IC50 of 205.3 ±23.5 nM that was 513-fold higher than
the mean IC50 of oseltamivir-sensitive isolates (n =3579)
(Table 1). The H275Y isolates also demonstrated elevated per-
amivir IC50 values (16.6 ±1.5 nM) that were approximately
80-fold higher than sensitive strains, but were fully sensitive to
zanamivir (Table 1). The oseltamivir-resistant viruses were
also resistant to the adamantane class of inﬂuenza antiviral
drugs based on M2 sequencing, having the characteristic S31N
substitution. These H275Y variants, including those from the
3 patients that received the inﬂuenza vaccine in 2011, were an-
tigenically indistinguishable from the oseltamivir-sensitive
viruses and were well inhibited by ferret serum samples raised
against the current A(H1N1)pdm09 vaccine strain A/Califor-
nia/7/2009 in a hemagglutination-inhibition assay (Supple-
mentary Table 1).
Phylogenetic analysis of the hemagglutinin and NA se-
quences revealed that the oseltamivir-resistant viruses from
Table 1. NA Inhibitor Sensitivity of Hunter New England Health District Oseltamivir-Resistant H275Y Viruses
Virus
Zanamivir Oseltamivir Carboxylate Peramivir
Mean IC50±SD (nM) Fold Diff
a Mean IC50±SD (nM) Fold Diff
a Mean IC50±SD (nM) Fold Diff
a
Mean of HNE health district
H275Y A(H1N1) pdm09
viruses (n=11)
0.3± 0.02 1 205.3±23.5 513 16.6± 1.5 83
Mean of HNE health district
sensitive A(H1N1) pdm09
viruses (n=65)
0.4± 0.2 1 0.5±0.3 1 0.2± 0.1 1
Mean of all sensitive A(H1N1)
pdm09 viruses (n=3579)
0.3± 0.2 … 0.4±0.3 … 0.2± 0.1
b …
A/Newcastle/2/2011 0.3± 0.02 1 191.1±19.4 478 18.6± 6.8 93
A/Newcastle/17/2011 0.3± 0.04 1 223.7±14.2 559 18.0± 2.3 90
A/Newcastle/37/2011 0.3± 0.1 1 247.9±27.2 620 16.9± 0.8 85
A/Newcastle/53/2011 0.2± 0.04 1 187.8±30.0 470 13.8± 1.2 69
A/Newcastle/62/2011 0.2± 0.04 1 199.9±19.7 500 15.9± 1.7 79
A/Newcastle/82/2011 0.2± 0.1 1 198.5±36.2 496 15.2± 1.5 76
A/Newcastle/85/2011 0.2± 1.1 1 226.6±11.4 567 16.7± 1.3 83
A/Newcastle/89/2011 0.3± 0.04 1 227.8±13.1 569 16.9± 1.8 85
A/Newcastle/132/2011 0.3± 0.04 1 198.1±26.8 495 15.8± 1.5 79
A/Newcastle/151/2011 0.2± 0.02 1 191.0±46.6 478 15.9± 2.2 79
A/Newcastle/129/2011 0.3± 0.03 1 165.9±26.1 415 18.8± 2.7 94
Abbreviations: Diff, difference; HNE, Hunter New England; IC50, inhibitory concentration.
a Based on comparison with mean IC50 of all sensitive A(H1N1)pdm09 viruses.
b Mean and standard deviation of peramivir IC50 values based on analysis of n =273 isolates.
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Sydney and Orange, and the Western Australian strain from
September 2011 were all highly similar (99.9% nucleotide sim-
ilarity across 22 HA and 18 NA sequences) and formed a dis-
tinct subgroup in both the HA and NA phylogenetic trees
(Figure 4). Apart from the H275Y NA substitution, the oselta-
mivir-resistant strains all contained 2 other NA amino acid
substitutions, V62I and N386S, which were absent from all
but 1 of the local oseltamivir-sensitive viruses (A/Newcastle/
84/2011) (Figure 4). In addition to the NA substitutions,
whole-genome sequence comparison of 8 oseltamivir-resistant
strains and 5 oseltamivir-sensitive strains from the HNE
health district revealed 3 further substitutions across 3 other
segments that were speciﬁc to the resistant strains—E129K in
HA, L672F in PA, and S482N in NP. Genetic comparison of
the 2 viruses from each of the linked cases showed 100%
nucleotide similarity across the HA and NA genes, although
sequence data were not available for viruses from 2 of the
paired cases. In addition, other oseltamivir-sensitive A(H1N1)
pdm09 strains, including A/South Australia/24/2011 and
A/Hong Kong/2973/2011, clustered phylogenetically with the
resistant strains (Figure 4), sharing a high degree of genetic
similarity, except for the H275Y NA substitution. Full phylo-
genetic trees comparing the HNE health district sequences
with publically available 2011 A(H1N1)pdm09 HA and NA
sequences are shown in the supplementary data (Supplemen-
tary Figure 1A and 1B).
Computational Analysis of Potentially Permissive NA
Substitutions
To investigate the role of potentially permissive NA mutations
that may be responsible for offsetting the negative effects of
the H275Y substitution, a computational analysis of NA
protein stability was conducted. Since the emergence of the A
(H1N1)pdm09 strain in 2009, a number of NA mutations
have been described and, in some cases, have become ﬁxed
Figure 4. Phylogenetic trees of hemagglutinin (A) and neuraminidase (B) sequences of oseltamivir-resistant H275Y variants and oseltamivir-sensitive
wild type A(H1N1)pdm09 viruses. Hunter New England health district and other NSW and Western Australian H275Y variants are shown in red,
sporadic H275Y mutants from other regions in green, and Hunter New England health district sensitive viruses in blue. Amino acid mutations common
to each clade and bootstrap conﬁdence values >75 are indicated on the trees.
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tational analysis, 2 of these mutations, V241I and N369K,
both of which emerged in A(H1N1)pdm09 viruses in 2010
and are now present in over 80% of currently circulating
strains (Figure 5), could restore approximately 50% of the
protein stability that was lost as a result of the H275Y muta-
tion (Figure 6). In addition, the HNE health district and other
NSW oseltamivir-resistant viruses contained an N386S NA
substitution. This substitution is less common in other A
(H1N1)pdm09 viruses, but computational analysis suggested
that it would also further stabilize the NA (Figure 6). Another
NA substitution that has been on the rise in recent strains and
was present in the oseltamivir-resistant viruses described here
is N44S. It creates a new potential N-glycosylation site at posi-
tion 42, changing the motif at positions 42–44 from NQN to
NQS. However, this region of the NA is in the stalk and not
part of the globular domain and, therefore, is not known how
it would affect NA structure and stability.
Discussion
The H275Y variants detected in the HNE health district, other
parts of NSW, and in Western Australia represent the largest
and most widespread cluster of oseltamivir-resistant A(H1N1)
pdm09 inﬂuenza identiﬁed since the virus ﬁrst emerged in
humans in 2009. The oseltamivir-resistant strains detected
from these locations were virtually identical genetically, sug-
gesting emergence from a single source.
The rapid global spread of oseltamivir-resistant seasonal A
(H1N1) H275Y viruses during 2007–2008 [11,12] showed
that A(H1N1) inﬂuenza viruses with this substitution could
retain transmissibility, even though previous in vitro and in
vivo studies found the substitution reduced ﬁtness in other A
(H1N1) strains [13,14]. A recent study demonstrated that sea-
sonal A(H1N1) oseltamivir-resistant H275Y viruses exhibited
reduced susceptibility to postvaccination antibody inhibition
compared to the cocirculating oseltamivir-sensitive viruses
Figure 5. All human A(H1N1)pdm09 NA sequences containing date information (at least year/month) were downloaded from the National Center for
Biotechnology Information inﬂuenza virus resource [41]( http://www.ncbi.nlm.nih.gov/genomes/FLU/) and GISAID (http://www.gisaid.org) and merged
with the ones reported in this study (keeping only 1 per unique strain identiﬁer). Sequences shorter than 90% of the median length are considered as
fragmentary and were removed from the analysis. The resulting 8085 sequences were then aligned with the multiple sequence alignment program
MAFFT [42] and mutation frequencies relative to the vaccine reference strain A/California/07/2009 counted with a custom perl script. All mutations
with at least 50 occurrences since March 2009 and global frequencies >20% in any month are shown, plus L415M, which is characteristic for an
outbreak with H275Y in Japan in January. Data collected in the month of March 2009 were merged with April 2009, while data collected from
September 2011 were merged with August 2011 as there were less than 10 sequences in those months.
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of the oseltamivir-sensitive seasonal A(H1N1) strain within 1
year. Based on antigenic analyses with postinfection ferret
serum samples, the oseltamivir-resistant A(H1N1)pdm09
H275Y viruses reported here are antigenically similar to osel-
tamivir-sensitive A/California/7/2009-like A(H1N1)pdm09
strains circulating in the HNE health district and elsewhere in
Australia, although future studies using postvaccination
human serum should be performed [30]. The high frequency
of resistance in untreated community patients suggests that
they are not markedly less ﬁt than sensitive viruses. This situa-
tion is similar to the oseltamivir-resistant seasonal A(H1N1)
viruses that emerged in Norway in 2007 where, like Australia,
the use of oseltamivir was low compared to countries such as
Japan and the United States [31].
Recently, it has been shown that certain substitutions in the
NA, V234M and R222Q, enabled the seasonal A(H1N1) virus
to remain fully functional in the presence of the H275Y sub-
stitution [32,33]. These permissive substitutions are not
present in the A(H1N1)pdm09 oseltamivir-resistant H275Y
variants reported here. Most A(H1N1)pdm09 sequences (in-
cluding the strains reported here) have the nonpermissive V at
position 234, and the most typical amino acid at position 222
among the A(H1N1)pdm09 NAs is N. However, 3 other NA
substitutions, V241I, N369K, and the N386S, which were
present in the oseltamivir-resistant strains from the cluster re-
ported here, may offset the destabilizing effect of the H275Y
substitution. The V241I and N369K substitutions are present
not only in the H275Y variants reported here, but are also in
viral sequences of North American and a large number of Jap-
anese oseltamivir-resistant H275Y strains recently deposited
on the GISAID sequence database (Supplementary Figure 1A
and 1B). Importantly, the N369K substitution, which compu-
tationally was predicted to cause the largest change in protein
stability, has previously been shown experimentally to increase
NA surface expression and activity in combination with
H275Y [32].
Infection with oseltamivir-resistant seasonal A(H1N1)
viruses signiﬁcantly reduced the effectiveness of oseltamivir
during the 2008–2009 season, particularly in younger children
[15–18]. For patients infected with oseltamivir-resistant
viruses, fever levels were comparable between oseltamivir-
treated and untreated patients, but signiﬁcantly reduced in za-
namivir-treated patients [15]. Mean duration of fever after the
start of oseltamivir treatment was also signiﬁcantly longer in
persons infected with oseltamivir-resistant viruses than in
those infected with oseltamivir-sensitive viruses [15,17,18],
while treatment of the H275Y viruses with zanamivir reduced
fever duration to normal levels [18]. Although the relationship
between in vitro IC50 of a virus and clinical effectiveness is not
well understood, it is noteworthy that the mean oseltamivir
IC50 of the H275Y A(H1N1)pdm09 viruses is generally lower
than that of the H275Y seasonal A(H1N1) variants [12,34,
35], and is below the steady-state trough plasma concentra-
tions found in children, adolescents, and adults following rec-
ommended dosing [36]. As a result, oseltamivir treatment may
be more effective for the A(H1N1)pdm09 H275Y variant than
has been reported for the H275Y seasonal A(H1N1) variants.
Figure 6. Computational structural analysis of combinations of candidate permissive mutations in the neuraminidase (NA). Mutations were modeled
with FoldX in the A(H1N1)pdm09 NA crystal structure (PDB:3nss) after minimization and using 5 repetitions.
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treatment of A(H1N1)pdm09 H275Y viruses, and other vari-
ants with reduced oseltamivir sensitivity, are needed. Eleven of
the oseltamivir-resistant HNE health district cases received
oseltamivir after specimen collection but, because the resistant
virus was detected after the patient had recovered and treat-
ment had ceased, it was not possible to investigate the effec-
tiveness of oseltamivir. The effectiveness of peramivir is also
likely to be reduced for the treatment of H275Y A(H1N1)
pdm09 viruses given the 80-fold increase in IC50 [37], as such
current WHO guidelines state that intravenous peramivir
should only be considered for the treatment of such viruses
when intravenous zanamivir is not available [38]. However,
recent animal data suggest that 5 days of therapy with intrave-
nous peramivir may overcome the shift in sensitivity to pera-
mivir caused by the H275Y substitution [39]. Given that the
H275Y variant is fully susceptible to zanamivir in vitro, this
drug remains the recommended alternative antiviral treatment
option when oseltamivir resistance is detected [38].
Of the 29 H275Y A(H1N1)pdm09 viruses detected in the
HNE health district, none caused severe illness or resulted in
patients being admitted to intensive care wards. However,
because detailed clinical or epidemiological information was
not collected at the same time from a comparison group of
patients with oseltamivir-sensitive virus infections, it was not
possible to determine whether there were any differences
between the types of patients infected or the types of illness
caused by oseltamivir-sensitive and -resistant viruses. Another
limitation is that a relatively small number of A(H1N1)pdm09
viruses were available for testing (191 from the HNE health
district and 737 from the rest of Australia). Therefore, not
only may the true prevalence of resistance be different to that
reported here, but the spread of the genetically related oselta-
mivir-resistant virus may also be wider than detected.
Inﬂuenza activity in the HNE health district and the rest of
Australia has now returned to baseline levels, although the
detection of the variant outside the HNE health district is
concerning and demonstrates its capacity to spread widely.
Oseltamivir-resistant strains that were indistinguishable to
those detected in the HNE health district were identiﬁed in
Sydney, the largest city in Australia and a large international
travel hub, and near Perth, Western Australia, on the other
side of the country to Newcastle. To date, there is no indication
that this oseltamivir-resistant A(H1N1)pdm09 strain has
spread into the northern hemisphere, although it will be
important for countries to monitor strains throughout the
upcoming northern hemisphere inﬂuenza season. The most
recent A(H1N1)pdm09 sequences strains deposited on
GISAID at the time of writing are from the United States
(Hawaii, California, Pennsylvania), and although none of them
have the H275Y substitution, they all have the NA substitu-
tions V241I and N369K, which may buffer the detrimental
effect of the H275Y oseltamivir-resistance mutation. The other
non-NA amino acid substitutions in the oseltamivir-resistant
viruses from the cluster (HA, PA, and NP) may also play a role
in viral ﬁtness. In vitro and in vivo studies are currently in
progress to analyze the ﬁtness of the strains from this cluster
and investigate the role of these potentially “permissive” muta-
tions. However, this cluster of cases, along with the recent
reports of increased detection of H275Y A(H1N1)pdm09
viruses in untreated community patients in the United
Kingdom and United States [24,40] and the large number of
recent sequences with the H275Y substitution deposited on
GISAID from Japan, suggests that the currently circulating A
(H1N1)pdm09 may be becoming more tolerant of the H275Y
mutation than it was when the strain ﬁrst emerged in 2009,
and that widespread emergence of oseltamivir-resistant A
(H1N1)pdm09 viruses may now be more likely.
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